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Summary A study was made evaluating the use of radiation-induced cell cycle delay in lymphocytes to predict tumour response to
radiotherapy. Peripheral blood lymphocytes were isolated from whole blood from 49 patients with head and neck cancer before treatment with
radiotherapy and from 25 healthy donors. The clinical response to radiotherapy was assessed at 0-2 months after treatment. The level of
radiation-induced cell cycle delay was measured using flow cytometry after mitogen stimulation of lymphocytes. The analysis of ten normal
donors gave no significant difference in variability between the intra-assay and the intra-donor samples. However, the cell cycle data for
lymphocytes from these healthy donors showed significant inter-individual differences in G2 phase accumulation. Patients showing no
response to radiotherapy had a high level of S-phase cells compared with partial (P< 0.001) and complete responders (P= 0.016). An inverse
relationship was found when analysing the fraction of cells in G2 (P= 0.009 and 0.034 respectively). In general, healthy donors had similar cell
cycle kinetics compared with the non-responders. In conclusion, the result indicates that radiation-induced cell cycle delay in lymphocytes is
inversely correlated with tumour response to radiotherapy in head and neck cancer patients. However, the value of the present test for
predicting individual tumour response is limited, because of assay variability and overlap between groups.
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Several studies have described potentially useful assays for
predicting patients' response to radiotherapy (RT). Traditionally,
tests of intrinsic tumour radiosensitivity have made use of either
colony-forming (West et al, 1991) or population-growth assays
(Brock et al, 1989), but there is an abundance of other approaches
(West, 1994). Recently, there has been increasing interest in normal
tissue radiosensitivity assays that use skin fibroblasts or peripheral
blood lymphocytes (PBLs). The ability of these assays to predict
normal tissue response to RT in individual cancer patients has been
tested (Bentzen, 1997). It is also interesting to assess whether or not
normal tissue radiosensitivity also reflects tumour radiosensitivity.
Dahlberg et al (1993) reported a correlation in radiosensitivity
between sarcoma cells and fibroblasts derived from the same
patient. Also, Geara et al (1996) found an association between
normal tissue reaction and tumour radiosensitivity in head and neck
cancer patients after definitive RT. These studies suggest that there
are common genetic factors that govern the individual radio-
sensitivity in both normal tissue and tumour cells.
The use of PBLs in predicting an individual's radiosensitivity is
attractive, as PBLs are easily collected and usually rapidly
assayed. Most of the studies that use PBLs from healthy donors
demonstrate no evidence for interindividual variation in radio-
sensitivity (Green et al, 1991; Nakamura et al, 1991; Geara et al,
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1992), nor a correlation between in vitro radiosensitivity of PBLs
and in vitro or in vivo radiation response of other cell types
(Kushiro et al, 1990; Green et al, 1991; Geara et al, 1992, 1993).
Only a few studies have shown significant differences in the
radiosensitivity of PBLs from one person to another (Elyan et al,
1993; Ramsay and Birrell 1995; West et al, 1995).
In the present study, we irradiated mitogen-stimulated PBLs
from head and neck cancer patients and measured accumulation of
cells in S- and G2 phases. These kinetic data were compared with
outcome of RT, which was given with curative intent. PBLs from
healthy donors were used for comparison and analysis of intra-
donor and intra-assay variability.
MATERIALS AND METHODS
Cell material and clinical data
PBLs were collected from heparinized blood of 93 patients at
Radiumhemmet with head and neck cancer before the start of RT,
as well as from 16 healthy donors (HI) without any history of
cancer. In addition, we investigated PBLs from ten healthy donors
(H2) for the analysis ofintra-donor and intra-assay variability. We
excluded 44 patients because of technical (21 individuals: < 5000
cells per histogram, <10% S + G2 background cells, too many
aggregates or technical hitch) or clinical reasons (23 individuals:
clinical information missing, post-operative radiation or no radia-
tion given/not 'full dose'). One healthy donor was excluded
because ofa technical reason. The range ofpatient ages was 41-92
years (mean 64 years), while the ages ofthe healthy donor popula-
tion ranged from 25 to 67 years, with a mean of 42 years. Thirty-
six (73%) of the included 49 patients and five (33%) of the 15
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aM, male; F, female. bTNM, tumour node metastasis. cType of clinical response afterfull-course radiotherapy with a final tumour absorbed dose of 64 Gy. CR,
complete responders; PR, partial responders; NR, non-responders. dMean fraction of cells passing to G2 phase after X-ray irradiation, relative to background.
healthy controls were male. External RT was delivered with
4-8 MV X-rays in daily fractions of2 Gy, five fractions per week,
with a final tumour-absorbed dose of 64 Gy. Sampling of blood
from the patients was approved by the medical ethical committee
ofthe Karolinska Institute.
Our patient material covers patients with various types of squa-
mous cell carcinoma ofthe head and neck, and Table 1 lists the site
and stage distributions. The categories ofclinical remission at the
end of RT and/or in the following 2-month period are: complete
response (CR), a complete disappearance of the tumour; partial
response (PR), 50-99% decrease of tumour size (the product of
two perpendicular diameters); no response (NR), 0-49% decrease
in tumour size. Clinical information on type of remission was
analysed in a blinded fashion. The code was then broken and
clinical remission was compared with the in vitro findings.
Cell culture, irradiation and flow cytometry
The PBL fraction along with other mononuclear cells was isolated
from blood samples by differential centrifugation in lymphoprep
(Nycomed, density 1.077, speed 750g at 4°C for 20 min). The
mononuclear preparation was purified of macrophages using the
British Journal ofCancer (1998) 77(4), 643-649 0 CancerResearch Campaign 1998Radiation-induced cell cycle delayin lymphocytes 645
technique of iron absorption. The cells were then stimulated using
a combination of6 jig ml' concanavalin A (Con A) and 25 ng ml-'
phorbol 12-myristate 13-acetate (PMA). These drugs were used
because of their combined effects in initiating two different path-
ways that participate in cell activation and cell cycle progression
(Crabtree, 1989). Cells were incubated at 37°C in RPMI 1640
medium supplemented with 10% fetal calf serum, 1% Hepes
buffer, L-glutamine (2 mM) and PEST (penicillin 2.4 IU ml-' and
streptomycin 2.4 jig ml-'). The initial concentration of cells in
culture was 2.5-3.5 x 106 cells ml-'. Twenty-four hours after
mitogen stimulation the cells were irradiated (0, 2, 4 and 8 Gy) in
culture medium at ambient room temperature (Siemens, 250 kV,
15 mA, 0.5-mm Cu-filter, SSD 50 cm, 0.81 Gy min-'). After a
further 48 h of incubation at 37°C, the cells were fixed.
For single-parameter DNA analysis, the cells were fixed in
phosphate-buffered formalin (4% formaldehyde (w/w), 29 mM
sodium dihydrogenphosphate x 2 H20, 47 mm disodium hydro-
genphosphate x 2 H20, pH 7.0) at different times up to 72 h after
mitogen stimulation. After a fixation time of about 16 h, the
formalin was replaced by 95% ethanol and the samples were kept
at 4°C. The cells were then incubated in distilled water, treated
with subtilisin Carlsberg (0.1% Sigma protease XXIV, 0.1 M Tris,
0.07 M sodium chloride, pH 7.5) and stained by adding DAPI-
SR101 solution (8 jiM DAPI, 50 jM sulphorhodamine 101, 0.1 M
Tris, 0.07 M sodium chloride, pH 7.5) (Castro et al, 1993). For
two-parameter DNA-protein analysis, the cells were directly fixed
in 95% ethanol and kept at 4°C. The staining was performed using
DAPI-SRIO solution (8 gM DAPI, 50 jUM sulphorhodamine 101,
0.1 M Tris, 0.07 M sodium chloride, pH 7.5) as described before
(Heiden et al, 1990). All flow analyses were performed using
a PAS II flow cytometer (Partec, Munster, Germany). Up to
50 000 cells were measured per histogram. The protein analysis
was internally standardized using fluorescent beads (6.4,m
Polychromatic beads; Polysciences, Warrington, CA, USA).
During a 10-month period, the analysis of mouse Ehrlich ascites
tumour cells fixed in 95% ethanol was repeated using the beads as
an internal reference. The mean ± s.d. of the protein values in G,
cells was 109.8 ± 8.4 (n = 10), which demonstrates a good
reproducibility of the protein analysis. Gating analysis and
calculations of protein median values were performed with the
help ofthe PAS II software. For calculation ofcell cycle composi-
tion, the Multicycle program (Phoenix Flow Systems, San Diego,
CA, USA) was used.
We found that, 24 h after the start of mitogen stimulation, cells
had entered the G, phase (Figure 1) and, 48 h later, approximately
25% of the cells were in S + G2 (Figures 1 and 2), without
changing the total cell number (data not shown). Hence, very few,
if any, cells had entered a second cell cycle. Samples with < 10%
S + G2 in unirradiated cells 72 h after start of mitogen stimulation
were excluded from further evaluation.
Definition of variables used
G,(D), S(D) and G2(D) represent the proportion ofGI, S- and G2
phase cells, respectively, after exposure to dose D. FG2(D) =
G2(D)I[G2(D) + S(D)] determines the fraction of cells passing to
G2 after exposure to dose D, as related to the population of prolif-
erating cells. For each patient and healthy donor, the response vari-
ables analysed were S(D)/S(0) and FG2(D)/FG2(0). These relative
S- and G2-phase fractions describe the response to dose D as
related to background.
Gsb.dn.aMuM
Figure 1 Protein analysis of gated Go/, lymphocytes at different times after
mitogenic stimulation. The histograms show a serial analysis of cells from
one healthy donor. In addition, the fractions of S + G/M cells are shown. The
histogram at the bottom shows the correlated DNA-protein analysis at 72 h.
The rectangle labels the GO, gating window. In all analyses, internal standard
beads were measured in DNA channel number 0 and the protein channel
number 64, which is marked by S. The median protein values of the Go/1 cells
were calculated in each histogram and the means ± s.d. of these protein
values were calculated for several donors (triangle, mean; solid line, s.d.).
0h,81±7(n=3);24h, 117±42(n=16);72h, 166±55(n=4).The24-h
mean protein GO/1 value does not differ significantly from either the 0-h value
(P = 0.16) or the 72-h value (P= 0.06). The 0-h value differs significantly
from the 72-h value (P = 0.048)
Statistical analysis
The data sets, based on the three different clinical responder
groups and the two healthy donor groups, were analysed by
repeated measurement ANOVA. Tests of differences between
groups, differences in dose dependence between individuals and
between groups (i.e. presence of dose-group interaction) were
carried out. Pairwise comparisons were also carried out by
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Figure 2 Percentages of peripheral blood lymphocytes from two individuals
in the various cell cycle phases at different times after stimulation with PMA
and Con A. *, Go/,; A, S; *, G/M. The inset shows two representative DNA
histograms of lymphocytes at 0 (top) and 72 (bottom) h after stimulation.
x-axis, relative DNA content per cell; y-axis, relative cell number
defining appropriate contrasts. In the analysis of donor and assay
variability, in which each donor had five determinations, tests
exploring inter-donor variability, dose dependence and
dose-donor interaction were performed. Comparisons of intra-
assay and intra-donor variation have been carried out comparing
the residual variance for the two groups ofhealthy donors.
The data variables, defined as the logarithm ofthe ratio between
the cell cycle phase values ofthe exposed and the control samples,
i.e. the natural logarithm of GI(D)/GI(O), S(D)/S(0) and
FG2(D)/FG2(0), were also subjected to two different kinds of
multivariate analyses. The first method used was a classificatory
discriminant analysis (Dillion and Goldstein, 1984). This analysis
was used to classify observations into two or more known groups
(five groups in the present material) on the basis of one or more
quantitative variables. The second method used was a cluster
analysis (Everitt, 1980), searching for five distinct groups of indi-
viduals based on the nine variables (i.e. different cell cycle stages
and radiation doses) for each subject; however this was in contrast
to the discriminant analysis, as the categorization was not used.
RESULTS
Analysis of healthy donor: intra-assay, intra- and inter-
donor variability
Analysis of intra-donor and intra-assay variability was carried out
using blood samples from ten normal donors. Fresh blood samples
from five donors were split into five aliquots and processed for the
analysis ofintra-assay variability. The remaining five donors were
resampled at five different times for the analysis of intra-donor
variability. Figures 3A and B show the dose dependence ofthe two
end points for each individual. The dose-response effect is highly
significant for both end points (P < 0.001). The analysis shows a
significant overall variation between donors for relative S-phase
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Figure 3 (A) Dose-response curves for ten healthy donors expressed as
the fraction of cells passing to S-phase, relative to background. Donors 1-5
represent split samples and 6-10 resampled donors. (B) Dose-response
curves for ten healthy donors expressed as the fraction of cells passing to G2
phase, relative to background. Donors 1-5 represents split samples, and
6-10 resampled donors
fraction (P < 0.001) but not for relative G2 phase fraction
(P = 0.93). However, for the S-phase fraction, this inter-donor
variation is almost totally accounted for by a single person (donor
3). The dose-donor interaction has also been tested for both end
points and was found to be significant for relative G2 phase frac-
tion (P < 0.001) but not for relative S-phase fraction. Donor 3
deviates with no increase in response from 4 to 8 Gy and, when
this donor is excluded, the effect on relative G2 phase fraction for
dose-donor interaction is only marginal. No significant difference
in variability between the intra-assay (donors 1-5) and the intra-
donor (donors 6-10) samples could be detected. The results
obtained in the intra-assay and intra-donor test showed, forthe two
analyses, both high and low degrees ofreproducibility at the indi-
vidual level. However, the donor heteroscedasticity in the group of
healthy controls is clearly dominated by the intra-assay variability.
Analysis of head and neck cancer patients and healthy
donors
The clinical information, including the clinical response to RT, is
summarized in Table 1 together with the relative G2 phase data.
Thirty-seven patients achieved a CR, seven patients a PR and the
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Table 3 Result of discriminant analysis: observed type by predicted typea
Predicted type
Group CR PR NR Hi H2 Total
CR 17 5 6 5 3 36
PR 0 6 0 0 0 6
NR 0 0 5 0 0 5
Hi 2 0 0 13 0 15
H2 0 0 0 0 10 10
Total 19 11 11 18 13 72
aTwo patients were not admissible for analysis because of zero value in
S-phase for one CR (8 Gy) and for one PR (4 Gy).
2 4 8
Dose (Gy) Table 4 Result of cluster analysis: observed type by cluster typea
Cluster type
Group 1 2 3 4 5 Total
CR 2 9 6 9 10 36
PR 1 4 0 0 1 6
NR 0 1 3 1 0 5
Hi 0 0 4 11 0 15
H2 0 0 0 10 0 10
Total 3 14 13 31 11 72
aTwo patients were not admissible for analysis because of zero value in
S-phase for one CR (8 Gy) and for one PR (4 Gy).
2 4 8
Dose (Gy)
Figure 4 (A) Dose-response curves for 49 head and neck cancer patients
with different remission after conventional radiotherapy and 15 healthy
donors expressed as mean ± s.e.m. fraction of S-phase cells, relative to
background, in peripheral blood lymphocytes at 72 h after mitogen
stimulation and 48 h after irradiation with 2, 4 or 8 Gy. 0, CR (n = 37); A, PR
(n = 7); *, NR (n = 5); 0, Hi (n = 15). (B) Dose-response curves for 49 head
and neck cancer patients with different remission after conventional
radiotherapy and 15 healthy donors expressed as mean ± s.e.m. fraction of
cells passing to G2 phase, relative to background. Cells were assayed as
above. 0, CR (n= 37); A, PR (n= 7);E, NR (n= 5); 0, Hi (n= 15)
Table 2 Significance for pairwise comparisons between groupsa
CR PR NR Hi
CR 0.019 0.016 <0.001
PR 0.19 <0.001 < 0.001
NR 0.034 0.009 0.55
Hi 0.056 0.016 0.4
aThe values above the diagonal correspond to the S-phase end point and the
values under the diagonal to the G2 phase end point.
remaining five patients belonged to the group of NR. Figure 4A
shows the mean ± s.e.m. of the relative S-phase fraction for each
group. Statistical analysis shows that there is a difference in the
level of response between the four groups (i.e. the three patient
groups and the HI group; overall test P < 0.001). There is also
a clear overall dose-response (P < 0.001) but no significant
dose-group interaction (P = 0.69). Figure 4B shows the corre-
sponding means ± s.e.m. ofthe relative G2 phase fraction for each
group. Analysis of this end point shows a difference between
the four groups (overall test P = 0.016) and a significant
dose-response (P = 0.034) but no significant dose-group interac-
tion (P = 0.43). Table 2 displays the significance for the pairwise
comparison between the different groups. The values above the
diagonal correspond to the P-values of the S-phase comparisons
and show that CR differed significantly from both HI, NR and PR.
As can be seen in Figure 4A, the relative S-phase values in the CR
group were lower than in the HI and NR and higher than in the PR
group. Figure 4B shows that the relative G2 fractions in the CR
group were higher than in the NR group and that the values of the
PR cases were higher than in both HI and NR. Table 2 shows that
these differences were statistically significant. None of the end
points showed any statistically significant correlation to tumour
site, stage, sex or age (P > 0.05).
Multivariate statistical analysis
Table 3 shows the results of a discriminant analysis. There is good
agreement between the predicted category and the observed cate-
gory for HI, H2, PR and NR, but not for CR. There is no overlap
between the two healthy donor groups (HI and H2). For PR and
NR, 100% of the patients were correctly classified. The second
type of multivariate method used was a cluster analysis. Table 4
shows how the five categories ofsubjects fall into the five clusters
found by the algorithm. Again CR seems to be difficult to catego-
rize falling with about equal proportions in clusters 2-5. Most of
the healthy donors fall into cluster 4, showing that the subjects in
the two healthy groups are 'close' to each other; most of the PR
and NR subjects belong to clusters 2 and 3.
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DISCUSSION
It is of interest to determine whether one can predict the radio-
sensitivity of tumour tissues based on evaluation of PBLs. In the
present study, we addressed this question for patients with head
and neck cancer scheduled for curative RT. The in vitro end point
was the fraction of PBLs passing to S and G, after irradiation. We
used early response as an in vivo indicator of tumour radiosensi-
tivity. Jaulerry et al (1995) showed that tumour regression during
and at completion of external RT (early response) is an indepen-
dent predictive factor of local control in head and neck. When
comparing accumulation of cells in S and G1, NR cases differed
from CR and PR cases in that they displayed higher S and lower
G, accumulation (Figures 4A and B). One may hypothesize that
these results reflect a difference in a radiation-sensitive cell cycle
checkpoint. As the cells were assayed 48 h after irradiation, the
exact position of such a checkpoint may be difficult to pinpoint.
NR cases may have a radiation-sensitive checkpoint in G, or S,
which is more effective than for CR and PR cases, whose PBLs
progress more efficiently to G, before they arrest. However, we
did not find it possible to predict NR for an individual patient,
because of variability between the groups. The PBLs from healthy
donors (HI) showed a response similar to that of the NR patients
and a significantly different cell cycle progression compared with
PR. The comparison with CR approached statistical significance
for the S-phase end point and reached significance for the G2
phase end point. Furthermore, discriminant and cluster analysis
show that grouping is possible. The discriminant analysis
presumes that subject categorization is known. Cluster analysis is
on the other hand an 'internal' method, in that the individuals are
not classified by any criteria other than the variables used in the
analysis. Using this latter approach, it was possible to categorize
most of the PR and NR subjects into clusters. The evidence
provided by this analysis does not need validation to the same
extent as the discriminant analysis as the a priori categorization
was not used. The result of this analysis underlines that there is
discriminating power in the measurements.
We also analysed PBLs from healthy donors to study the intra-
assay and intra-donor variability. Most of the individuals in the
two healthy donor groups (H1 and H2) were grouped into the
same clusters using multivariate analysis, which differs from the
dose-response seen when comparing the two groups (data not
shown). However, the H2 group was assayed almost 1 year after
the HI group, and this temporal difference might have had an
influence on our results. The overall variation in dose dependence
between healthy donors was significant in G, phase accumulation,
but as the intra-assay variability dominates over the variability
seen in the resampled donors, the interpretation is limited and not
yet fully understood.
Individuals vary in their sensitivity to ionizing radiation.
Defined disorders with radiosensitive phenotypes, such as the
ataxia-telangiectasia (AT) syndrome, show that genetic factors
can strongly determine the radiosensitivity of humans (Thacker,
1994). In addition, studies have revealed that cells from AT
heterozygotes show increased radiosensitivity (Cole et al, 1988;
Weeks et al, 1991; West et al, 1995). There are ongoing efforts to
evaluate a possible role of AT heterozygosity for over-reaction to
RT, particularly in breast cancer patients (Weeks et al, 1991; West
et al, 1995). From these studies, it can be observed that in vitro
sensitivity ofnormal cells from some cancer patients may fall into
a similar range, as AT heterozygotes do. Interestingly, recent
studies have reported changes in cell cycle kinetics after irradia-
tion of AT heterozygote lymphoblastoid cells that are similar to
those presented here (Lavin et al, 1992, 1994; Naeim et al, 1994).
Only a few studies have suggested the existence of a relation-
ship between normal tissue and tumour radiosensitivity. Dahlberg
et al (1993) reported a significant correlation between the
radiosensitivities of sarcoma cells and fibroblasts derived from the
same patient. Whether this correlation had a bearing on clinical
tumour response is not known. Furthermore, a recent study
suggests the association between tumour control and acute
mucosal reaction after RT (Geara et al, 1996). If genetic differ-
ences are abundant that influence intrinsic radiosensitivity ofboth
normal tissue and tumour response to RT, the measurements of
such differences could guide us to a more appropriate dosing of
RT. Usually the limiting factor in RT treatment is the maximum-
tolerated dose ofnormal tissue. The doses used in conventional RT
are relatively low to avoid problems in a radiosensitive subgroup
ofpatients. This may result in underdosage in most ofthe patients.
It has been estimated that identification of the most radiosensitive
individuals would allow the use of higher radiation doses in the
treatment ofthe remaining patients, without increasing side-effects
(Norman et al, 1988). Therefore, it would also be of great interest
to evaluate the relationship between the cell cycle kinetics ofPBLs
after in vitro irradiation and clinical normal tissue reponse to RT.
Lymphocytes are known to undergo apoptosis after irradiation
(Sellins and Cohen, 1987). The DNA histograms in the present
study show events in the sub-G, region in the stimulated (and irra-
diated) samples, as shown in Figures 1 and 2. This sign of DNA
loss or nuclear fragmentation indicates cell death. Thus, it is
possible that our observations of differences in cell cycle distribu-
tions are influenced by apoptosis that could occur with cell cycle
phase specificity. However, substantial cell cycle progression
occurs after stimulation of PBLs, and it is our impression that the
present results mainly reflect differences in cell cycle kinetics.
In conclusion, although the present assay showed a discrimi-
nating power between the clinical response groups, the results of
the test did not permit prediction ofindividual outcome ofRT with
satisfying accuracy.
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